Clinical and pharmacokinetic study with a lipidic prodrug of mitomycin-c entrapped in liposomes in metastatic colorectal cancer patients

被引：0
|
作者：
Gabizon, Alberto A. [1 ]
Tahover, Esther [1 ]
Perets, Ruth [2 ]
Golan, Talia [3 ]
Geva, Ravit [4 ]
Amitay, Yasmine [5 ]
Shmeeda, Hilary [1 ]
Ohana, Patricia [1 ]
机构：
[1] Shaare Zedek Med Ctr, Jerusalem, Israel
[2] Rambam Hlth Care Campus, Haifa, Israel
[3] Sheba Med Ctr, Ramat Gan, Israel
[4] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[5] Lipomedix Pharmaceut, Jerusalem, Israel
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT054
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer
    Gyldenkerne, N
    Glimelius, B
    Frödin, JE
    Kjaer, M
    Pfeiffer, P
    Hansen, F
    Keldsen, N
    Sandberg, E
    Jakobsen, A
    ACTA ONCOLOGICA, 2004, 43 (03) : 276 - 279
  • [22] Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Do Hyoung Lim
    Young Suk Park
    Byeong-Bae Park
    Sang Hoon Ji
    Jeeyun Lee
    Keon Woo Park
    Jung Hoon Kang
    Se-Hoon Lee
    Joon Oh Park
    Kihyun Kim
    Won Seog Kim
    Chul Won Jung
    Young-Hyuck Im
    Won Ki Kang
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 10 - 14
  • [23] Liposomal mitomycin C prodrug (Promitil) compared to mitomycin C in chemoradiotherapy in preclinical models of colorectal cancer
    Tian, Xi
    Minh Nguyen
    Ohana, Patricia
    Gabizon, Alberto A.
    Wang, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A phase 1B study of pegylated liposomal mitomycin-C prodrug with or without capecitabine and bevacizumab in third line chemotherapy of colorectal cancer
    Gabizon, A. A.
    Grenader, T.
    Tahover, E.
    Shmeeda, H.
    Golan, T.
    Berger, R.
    Geva, R.
    Wolf, I.
    Perets, R.
    Amitay, Y.
    Ohana, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Lim, DH
    Park, YS
    Park, BB
    Ji, SH
    Lee, J
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 10 - 14
  • [26] BLOOD DISPOSITIONS OF MITOMYCIN-C AND A LIPOPHILIC PRODRUG AFTER INTRAMUSCULAR AND INTRAVENOUS ADMINISTRATION IN LIPOSOMES AND O/W EMULSION
    SASAKI, H
    KAKUTANI, T
    HASHIDA, M
    KIMURA, T
    SEZAKI, H
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1985, 33 (07) : 2968 - 2973
  • [27] CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: A Belgian multicentre phase II study.
    Polus, M
    Peeters, M
    Baert, F
    Vergauwe, P
    Kalantan, H
    Hendrickx, K
    Collignon, J
    Van Maele, P
    Vandeputte, L
    Van Laethem, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 298S - 298S
  • [28] CHEMOTHERAPY WITH MITOMYCIN-C AND VINBLASTINE IN PRETREATED METASTATIC BREAST-CANCER
    PERRONE, F
    DEPLACIDO, S
    CARLOMAGNO, C
    NUZZO, F
    RUGGIERO, A
    DELAURENTIIS, M
    GRIDELLI, C
    PAGLIARULO, C
    BIANCO, AR
    TUMORI, 1993, 79 (04) : 254 - 257
  • [29] Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Alliot, C
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 935 - 936
  • [30] Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    C Alliot
    British Journal of Cancer, 2006, 94 : 935 - 936
12345